B · Normal
[Innovative drug concept shock adjustment and Heyuan Biotech fell more than 10%] On November 16, the innovative drug concept shock adjustment, Heyuan Biotech fell more than 10%, Sansheng Guojian, Junshi Biotech, Laimei Pharmaceutical, Yiqiao Shenzhou, and Bibet followed the decline.
Comments